Insomnia is a perceived disturbance in the quality or quantity of sleep, which, depending on the specific condition may be associated with disturbances in objectively measured sleep. Insomnia is a common subjective complaint of inadequate sleep that affects 15% to 40% of the general population, with 10% to 15% of individuals reporting chronic insomnia of 6 month\'s duration.
Dement WC. Normal sleep, disturbed sleep, transient and persistent insomnia. Acta Psychiatr Scand Suppl. 1986; 332:41-46.
Kripke DF, Simnos RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills. Is increased mortality associated? Arch General Psychiatry. 1979; 36103-116.
Katz DA, McHorney Ca. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med.1998;158:1099-1107.
Taylor DJ, Licstein KL, Durrence HH. Insomnia as a health risk factor. Behav Sleep Med.2003;1:227-247.
National Institutes of Health. NIH state of the science statement on manifestations and management of chronic insomnia in adults. J Clin Sleep Med 2005;1:412-21.
Basta M, Chrousos GP, Vela-Bueno A, Vgontzas AN. Chronic insomnia and the stress system. Sleep Med Clin 2007;2:279-91.
Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? J Clin Sleep med 2007; 3:489-94.
Suka M, Yoshida K, Sugimori H. Persiatent insomnia is a predictor of hypertension in Japenese male workers. J Occup helath 2003; 45:344-50.
Vogontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short duration is associated with Type 2 diabetes: A population-based study. Diabetes Care 2009.
Vogontzas AN, Liao D, Bixler EO,Chrousos GP, VelaBueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 2009; 1;32 (8): 977-8.
Summers, Michael, Crisostomo, Maria I, Stepanski Edward J. Recent developments in the classification, evaluation, and treatment of insomnia. (Postgraduate Education Corner: CONTEMPORARY REVIEWS IN SLEEP MEDICINE)(Disease/Disorder overview)1 July,2006.
Jadwija Najib. Eszopiclone: A Nonbenzodiazepine Sedative – Hypnotic agent for the treatment of Transient and Chronic Insomnia Clinical Therapeutics 2006;28:4.
Hohajen F, Kappler C, Shramn E, et. al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17(6): 551.
Lichstein KL, Durrrence HH, Taylor DJ, et.al. Quantitative criteria for insomnia. Behav Res Ther.2003; 41(4): 427- 445.
Affleck G, Urrowus S, Tennen H, et.al. Sequential daily relations of sleep pain intensity and attention to pain among women with fibromyalgia. Pain.1996; 68(2-3);363-368.
Benca Ruth M. Insomnia. Avidan AY, Zee PC., eds. Handbook of Sleep Medicine, New Delhi: Wolters Kluwer Health (India);2006:36-70
Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry 2007;7:42
Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res 2008;17:245-50.
Walsh JK. Drugs used to treat insomnia in 2002: Regulatory- Based rather than evidence –based medicine. Sleep. 2004; 27 (8): 1441-1442.
Holbrook AM, Crowther R, Lotter A, et al. Meta–analysis of benzodiazepine use in the treatment of insomnia. CMAJ.2000; 162(2): 225-233.
Saletu –Zyhlarz G, Anderer P, Brandstatter N, et al. Placebo controlled sleep laboratory studies on the acute effects of Zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress –related disorder. Neuropsychobiology 2000;41(3):139- 148.
Compton–McBride S, Schweitzer P, Walsh J, Most commonly used drugs to treat insomnia in 2002.Sleep.2004; 27 (suppl): A255.
Saletu–Zyhlarz GM, Abu–Bakr MH, Anderer P, et al. Insomnia in depression :differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsycopharmacol. Biol Psychiatry.2002;26 (2):249-260.
Sharpley AL, Vassallocm, Cowen PJ. Olanzapine increases slow– wave sleep: evidence for blockade of central 5-HT (2c) Receptors in vivo. Biol Psychiatry.2000; 47(5): 468- 470.
Witek TJ Jr, Canestrian DA, Miller RD, et al. Characterization of daytime sleepiness and psychomotor Performance following H1 receptor antagonist. Ann Allergy Asthma Immunol.1995; 74(5): 419-426.
Haimov I, Lavie P, Laubon M, et.al. Melatonin replacement therapy of elderly. Sleep. 1995; 18(7): 598 –603.